Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Next Previous
Trial Profile

An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASP 5878 (Primary)
  • Indications Bladder cancer; Breast cancer; Carcinoid tumour; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Leiomyosarcoma; Liver cancer; Lung cancer; Mesothelioma; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Astellas Pharma

Most Recent Events

  • 21 Mar 2020 Results of an analysis on extended systems model to describing changes in serum P, C, parathyroid hormone and Fibroblast growth factor receptor inhibition were presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 30 Apr 2019 Results published in the Investigational New Drugs Journal.
  • 12 Sep 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top